X
56.85
0.16 (0.28%)
| Previous Close | 56.69 |
| Open | 56.00 |
| Volume | 874,208 |
| Avg. Volume (3M) | 1,426,608 |
| Market Cap | 5,425,033,728 |
| Price / Sales | 598.74 |
| Price / Book | 9.29 |
| 52 Weeks Range | |
| Earnings Date | 11 May 2026 |
| Operating Margin (TTM) | -969.84% |
| Diluted EPS (TTM) | -3.22 |
| Total Debt/Equity (MRQ) | 1.23% |
| Current Ratio (MRQ) | 17.66 |
| Operating Cash Flow (TTM) | -196.85 M |
| Levered Free Cash Flow (TTM) | -128.49 M |
| Return on Assets (TTM) | -22.03% |
| Return on Equity (TTM) | -31.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Xenon Pharmaceuticals Inc. | Bullish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.25 |
|
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.14% |
| % Held by Institutions | 103.51% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Avoro Capital Advisors Llc | 31 Dec 2025 | 5,424,444 |
| Janus Henderson Group Plc | 31 Dec 2025 | 4,084,034 |
| Braidwell Lp | 31 Dec 2025 | 1,825,076 |
| Commodore Capital Lp | 31 Dec 2025 | 1,800,000 |
| Jennison Associates Llc | 31 Dec 2025 | 1,292,055 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 97.00 (Baird, 70.62%) | Buy |
| Median | 71.00 (24.89%) | |
| Low | 60.00 (Wolfe Research, 5.54%) | Buy |
| Average | 74.38 (30.84%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 56.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Deutsche Bank | 10 Mar 2026 | 90.00 (58.31%) | Buy | 60.61 |
| HC Wainwright & Co. | 10 Mar 2026 | 74.00 (30.17%) | Buy | 60.61 |
| Wedbush | 10 Mar 2026 | 64.00 (12.58%) | Buy | 60.61 |
| Wells Fargo | 10 Mar 2026 | 68.00 (19.61%) | Buy | 60.61 |
| 27 Feb 2026 | 49.00 (-13.81%) | Buy | 43.23 | |
| Baird | 09 Mar 2026 | 97.00 (70.62%) | Buy | 62.76 |
| Needham | 09 Mar 2026 | 80.00 (40.72%) | Buy | 62.76 |
| 27 Feb 2026 | 58.00 (2.02%) | Buy | 43.23 | |
| Wolfe Research | 24 Feb 2026 | 60.00 (5.54%) | Buy | 44.79 |
| JP Morgan | 09 Jan 2026 | 62.00 (9.06%) | Buy | 42.15 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Jan 2026 | Announcement | Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Jan 2026 | Announcement | Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference |
| 05 Jan 2026 | Announcement | Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |